Delcath Systems Inc (DCTH)

[JJAAMMAANN]

Delcath Announces Satisfaction of 2016 Convertible Note
GlobeNewswireFebruary 1, 2018
NEW YORK, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that it has satisfied all of its obligations under the privately placed senior secured convertible notes issued to two institutional investors in June 2016. On December 28, 2017, Delcath entered into exchange agreements with two institutional investors pursuant to which those investors were issued, in exchange for satisfaction in full of those notes, shares of its common stock (or rights to receive common stock to the extent such issuance of Shares would otherwise result in the beneficial ownership by any such investor of more than 4.9% or 9.9% of our issued and outstanding stock), as applicable, in an aggregate of 123,708,735 shares of our common stock. As of January 25, 2018, all of the Rights were exercised, and neither investor owns more than 4.9% of the issued and outstanding shares of Delcath’s common stock.